Vijaya Diagnostic Centre Limited has filed its Business Responsibility and Sustainability Report (BRSR) for the financial year 2025-26 with the Bombay Stock Exchange and National Stock Exchange of India Limited. The disclosure was made on August 26, 2026, pursuant to Regulation 34(2)(f) of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015.

The report forms part of the company's Annual Report for FY26. It provides a detailed overview of the entity's general disclosures, operational footprint, and performance against the nine principles of the National Guidelines on Responsible Business Conduct.

Operational Footprint

Vijaya Diagnostic Centre operates exclusively in India, serving six states: Telangana, Andhra Pradesh, Maharashtra, Karnataka, West Bengal, and the National Capital Region. As of the end of FY26, the company maintained 162 offices and laboratories across these locations. The entity reported no international operations or export contributions during the period.

The company's primary business activity involves providing comprehensive diagnostic services, including pathological investigations and radiology/imaging services. This segment accounted for 100% of the entity's turnover.

Financial Overview

Under the Corporate Social Responsibility section of the report, Vijaya Diagnostic Centre disclosed a turnover of ₹7,654.29 million and a net worth of ₹9,434.53 million for FY26. CSR provisions under Section 135 of the Companies Act, 2013, are applicable to the entity.

Employee Metrics

The company employed a total of 3,244 individuals at the end of FY26, comprising 2,507 permanent employees and 737 non-permanent staff. Women constituted 46% of the total workforce, with a higher representation among non-permanent employees (64%) compared to permanent roles (40%).

The turnover rate for permanent employees stood at 33.15% in FY26, an increase from 30.51% in FY25 and 29.98% in FY24. The board of directors includes four women, representing 40% of the total board strength.

Sustainability and Governance

Vijaya Diagnostic Centre highlighted several sustainability initiatives in its report:

• Energy Consumption: Total energy consumed from non-renewable sources was 74,288 Giga Joules in FY26, up from 56,775 Giga Joules in FY25.
• Waste Management: The company generated 99.24 metric tonnes of waste, primarily biomedical waste (98.23 metric tonnes), which was disposed of through authorized service providers.
• Renewable Energy: A 40-kW grid-connected rooftop solar power system at the Madhapur facility generated approximately 22.5 MWh of electricity annually.

The company reported no complaints regarding child labor, forced labor, or discrimination. It received 8,413 customer complaints related to the delivery of essential services, of which 141 were pending resolution as of March 31, 2026, but have since been resolved.

Vijaya Diagnostic Centre Limited announced its 24th Annual General Meeting will take place on September 24, 2026. The virtual meeting aims to approve financial results for FY26 and key corporate actions.

The Board recommends a final dividend of ₹2 per equity share for FY26. Shareholders on record as of September 16, 2026, will be eligible for the payout.

Corporate Actions

The agenda includes significant changes to employee compensation structures. The company seeks shareholder approval to increase the Employee Stock Option Pool under the VDCL Employee Stock Option Plan 2018.

This expansion adds 20,00,000 new stock options to the existing pool. The company has already granted 14,62,586 options from the original pool, leaving a residual balance of 1,62,414 options before this increase.

Governance Updates

Mrs. Sura Geeta Reddy retires by rotation and offers herself for re-appointment as a Non-Executive Director. She holds a law degree and serves on the Nomination & Remuneration Committee.

The meeting also seeks ratification for the remuneration of the Cost Auditor, M/s. TSSV Santhosh Kumar. The approved fee is ₹50,000 plus applicable taxes for the financial year ending March 31, 2027.

What the Numbers Show

The proposed ESOP expansion represents a substantial increase in potential equity dilution. By adding 20,00,000 options to the existing 16,25,000 pool, the total authorized options will more than double. This move aligns with the company's network growth from 81 to 162 diagnostic centres over the past five years, suggesting a strategic focus on retaining talent amid operational scale-up.